United States Pharmaceuticals

Hillevax Inc (HLVX)

Track

Ticker: HLVX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Hillevax Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 11 Feb 2025
Value US$817,032.70 | Price 357.53 | Shares 88,994 (-48.5%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-02-12 2025-02-11 S Sale
2.4
HERSHBERG ROBERT

See Remarks

Executive Director
88,994 -48.5%
357.53
US$817,033 		88,994 -48.5% 357.53 US$817,033
2025-02-12 2025-02-11 S Sale
2.5
Maltbie Shane

Chief Financial Officer

Officer
32,217 +41.2%
239.75
US$497,234 		32,217 +41.2% 239.75 US$497,234
2025-02-12 2025-02-04 S Sale
2.4
HERSHBERG ROBERT

See Remarks

Executive Director
91,618 -44.4%
197.88
US$526,766 		91,618 -44.4% 197.88 US$526,766
2025-02-12 2025-02-04 S Sale
2.5
Maltbie Shane

Chief Financial Officer

Officer
3,946 -4.5%
1.89
US$7,458 		3,946 -4.5% 1.89 US$7,458
2024-05-22 2024-05-22 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.8%
14.73
US$88,372 		6,000 -0.8% 14.73 US$88,372
2024-05-22 2024-05-21 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.8%
14.21
US$85,230 		6,000 -0.8% 14.21 US$85,230
2024-05-22 2024-05-20 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.8%
15.45
US$92,689 		6,000 -0.8% 15.45 US$92,689
2024-05-03 2024-05-03 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
723 -0.1%
14.15
US$10,233 		723 -0.1% 14.15 US$10,233
2024-05-03 2024-05-02 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.8%
14.01
US$84,081 		6,000 -0.8% 14.01 US$84,081
2024-05-03 2024-05-01 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
175 -0.0%
14.03
US$2,456 		175 -0.0% 14.03 US$2,456
2024-04-05 2024-04-05 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.8%
14.44
US$86,640 		6,000 -0.8% 14.44 US$86,640
2024-04-08 2024-04-04 B Purchase
0.8
Frazier Life Sciences X, L.P.
Large shareholder
8,850 +0.1%
14.50
US$128,325 		8,850 +0.1% 14.50 US$128,325
2024-04-05 2024-04-04 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
14.71
US$88,245 		6,000 -0.7% 14.71 US$88,245
2024-04-05 2024-04-03 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
14.93
US$89,582 		6,000 -0.7% 14.93 US$89,582
2024-04-01 2024-03-28 B Purchase
0.5
McLoughlin Sean

Chief Operating Officer

Officer
1,250 +inf%
16.98
US$21,225 		1,250 +inf% 16.98 US$21,225
2024-03-20 2024-03-20 PrS Proposed sale
2.1
ADITYA KOHLI

Director; Officer

Executive Director
54,000
17.43
US$941,220 		54,000 17.43 US$941,220
2024-03-20 2024-03-20 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
164,221.00
US$985,326,000 		6,000 -0.7% 164,221.00 US$985,326,000
2024-03-20 2024-03-19 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
17.42
US$104,492 		6,000 -0.7% 17.42 US$104,492
2024-03-20 2024-03-18 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
17.66
US$105,937 		6,000 -0.7% 17.66 US$105,937
2024-03-08 2024-03-08 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
18.66
US$111,959 		6,000 -0.7% 18.66 US$111,959
2024-03-08 2024-03-07 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
18.37
US$110,213 		6,000 -0.7% 18.37 US$110,213
2024-03-08 2024-03-06 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
18.95
US$113,701 		6,000 -0.7% 18.95 US$113,701
2024-02-22 2024-02-22 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
15.05
US$90,312 		6,000 -0.7% 15.05 US$90,312
2024-02-22 2024-02-21 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
14.92
US$89,495 		6,000 -0.7% 14.92 US$89,495
2024-02-22 2024-02-20 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
14.88
US$89,272 		6,000 -0.7% 14.88 US$89,272
2024-02-14 2024-02-12 PlS Planned sale
2.1
Kohli Aditya
Non-Executive Director
6,000 -0.7%
15.32
US$91,921 		6,000 -0.7% 15.32 US$91,921
2024-02-12 2024-02-12 PrS Proposed sale
2.1
ADITYA KOHLI

Director; Officer

Executive Director
54,000
15.00
US$810,000 		54,000 15.00 US$810,000
2024-02-12 2024-02-08 S Sale
1.8
Borkowski Astrid

Chief Medical Officer

Officer
3,933 -2.4%
14.93
US$58,726 		3,933 -2.4% 14.93 US$58,726
2024-02-12 2024-02-08 S Sale
2.4
HERSHBERG ROBERT

See Remarks

Executive Director
11,597 -1.2%
14.93
US$173,161 		11,597 -1.2% 14.93 US$173,161
2024-02-12 2024-02-08 S Sale
2.1
Kohli Aditya
Non-Executive Director
8,866 -1.1%
14.93
US$132,383 		8,866 -1.1% 14.93 US$132,383
2024-02-12 2024-02-08 S Sale
2.5
Maltbie Shane

Chief Financial Officer

Officer
3,576 -8.1%
14.93
US$53,395 		3,576 -8.1% 14.93 US$53,395
2024-01-22 2024-01-22 PrS Proposed sale
2.4
HERSHBERG ROBERT

Officer; Director

Executive Director
72,000
14.00
US$1,008,000 		72,000 14.00 US$1,008,000
2023-12-18 2023-12-15 PrS Proposed sale
1.8
Astrid Borkowski

Officer

Officer
10,000
15.50
US$155,000 		10,000 15.50 US$155,000
2023-12-18 2023-12-15 S Sale
1.8
Borkowski Astrid

Chief Medical Officer

Officer
10,000 -5.7%
15.50
US$155,000 		10,000 -5.7% 15.50 US$155,000
2023-12-05 2023-12-04 PrS Proposed sale
1.8
Astrid Borkowski

Officer

Officer
10,000
14.50
US$145,000 		10,000 14.50 US$145,000
2023-12-05 2023-12-04 S Sale
1.8
Borkowski Astrid

Chief Medical Officer

Officer
10,000 -5.4%
14.50
US$145,000 		10,000 -5.4% 14.50 US$145,000
2023-12-05 2023-12-01 PrS Proposed sale
1.8
Astrid Borkowski

Officer

Officer
10,000
14.20
US$142,000 		10,000 14.20 US$142,000
2023-12-05 2023-12-01 S Sale
1.8
Borkowski Astrid

Chief Medical Officer

Officer
10,000 -5.1%
14.20
US$142,000 		10,000 -5.1% 14.20 US$142,000
2023-11-27 2023-11-17 PrS Proposed sale
1.8
Borkowski Astrid

Officer

Officer
10,000
14.00
US$140,000 		10,000 14.00 US$140,000
2023-11-20 2023-11-17 S Sale
1.8
Borkowski Astrid

Chief Medical Officer

Officer
10,000 -4.9%
14.00
US$140,000 		10,000 -4.9% 14.00 US$140,000
2023-11-27 2023-11-08 PrS Proposed sale
1.8
Borkowski Astrid

Officer

Officer
5,000
13.00
US$65,000 		5,000 13.00 US$65,000
2023-11-13 2023-11-08 S Sale
1.8
Borkowski Astrid

Chief Medical Officer

Officer
5,000 -2.4%
13.00
US$65,000 		5,000 -2.4% 13.00 US$65,000
2023-06-20 2023-06-21 PrS Proposed sale
1.8
Astrid Borkowski

Officer

Officer
10,000
16.74
US$167,400 		10,000 16.74 US$167,400
2022-05-03 2022-05-03 B Purchase
0.8
Frazier Life Sciences X, L.P.
Large shareholder
1,764,706 +26.1%
17.00
US$30,000,002 		1,764,706 +26.1% 17.00 US$30,000,002
Explore more

More insider trading research around Hillevax Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America